New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
Hussar
Daniel A
DA
Pharmacy Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D000577:Amides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003913:Dextroamphetamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D005650:Fumarates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000077341:Lapatinib; D000069478:Lisdexamfetamine Dimesylate; D011355:Prodrugs / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013566:Sympathomimetics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D000577:Amides; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D000697:Central Nervous System Stimulants; D005650:Fumarates; D011355:Prodrugs; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D013566:Sympathomimetics; D000077341:Lapatinib; C446481:aliskiren; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine